A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04214288 |
|
Recruitment Status :
Active, not recruiting
First Posted : January 2, 2020
Results First Posted : December 12, 2023
Last Update Posted : March 7, 2024
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced ER-Positive HER2-Negative Breast Cancer | Drug: AZD9833 Drug: Fulvestrant | Phase 2 |
Post-menopausal women with histologically or cytologically confirmed metastatic or loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and fulfilling all of the inclusion criteria and none of the exclusion criteria will be included.
After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio to receive 1 of the following 4 treatments, consisting of 4-week treatment cycles until disease progression (assessed by the Investigator as defined by Response Evaluation Criteria in Solid Tumours [RECIST] version 1.1):
- AZD9833 (Dose A)
- AZD9833 (Dose B)
- AZD9833 (Dose C)
- Fulvestrant (500 mg) During the treatment period, patients will have scheduled visits until treatment discontinuation. After the end of treatment, patients will attend 2 safety follow-up visits (at the time of treatment discontinuation and 28 days later) and will continue to be followed for survival.
As of December 2020, the Sponsor stopped enrolment to Dose C.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 240 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer |
| Actual Study Start Date : | April 22, 2020 |
| Actual Primary Completion Date : | August 30, 2022 |
| Estimated Study Completion Date : | March 29, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: AZD9833 Dose A
The patients will receive AZD9833 (Dose A).
|
Drug: AZD9833
Dosage formulation: AZD9833 tablets will be administered orally. |
|
Experimental: AZD9833 Dose B
The patients will receive AZD9833 (Dose B).
|
Drug: AZD9833
Dosage formulation: AZD9833 tablets will be administered orally. |
|
Experimental: AZD9833 Dose C
The patients will receive AZD9833 (Dose C).
|
Drug: AZD9833
Dosage formulation: AZD9833 tablets will be administered orally. |
|
Active Comparator: Fulvestrant 500 mg
The patients will receive Fulvestrant (500 mg).
|
Drug: Fulvestrant
Dosage formulation: Fulvestrant will be administered via intramuscular (IM) injection. |
- Progression-free Survival (PFS) [ Time Frame: From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months) ]
PFS was assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1. PFS was defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or received another anti-cancer therapy prior to progression. Disease progression was defined as ≥20% increase in the sum of diameters of target lesions, unequivocal progression in non-target lesions, and/or appearance of new lesions.
Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
- Objective Response Rate (ORR) [ Time Frame: From screening until disease progression (up to data cut-off of 29 months) ]
ORR was assessed by the Investigator as defined by RECIST version 1.1. The ORR was defined as investigator assessed Complete Response or Partial Response prior to progression in patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Adjusted response rate was presented in this analysis.
Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
- Duration of Response (DoR) [ Time Frame: From screening until disease progression or last evaluable assessment in the absence of progression (up to data cut-off of 29 months) ]DoR was assessed by the Investigator as defined by RECIST version 1.1. The DoR was defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression.
- Percentage Change in Tumour Size at 16 Weeks [ Time Frame: At Week 16 ]The percentage change in tumour size at 16 weeks was obtained for each patient, based on RECIST measurements taken at baseline and at 16 weeks. Tumour size is the sum of the longest diameters of the target lesions (TLs). Percentage change in the sum of longest TLs diameters at 16 weeks was measured.
- Overall Survival (OS) [ Time Frame: From the date of randomisation until death (up to data cut-off of 29 months) ]The OS was defined as the time from randomisation to death due to any cause.
- Clinical Benefit Rate at 24 Weeks (CBR24) [ Time Frame: At Week 24 ]
Clinical benefit rate was defined as patients with best objective response of complete response or partial response in the first 25 weeks or who have stable disease for at least 23 weeks after randomization.
Adjusted response rate was presented in this analysis.
Data from the 300mg arm should be interpreted with caution as recruitment to the 300mg arm was stopped early at 20 patients randomised and therefore the 300mg data is highly variable.
- Plasma Concentrations of AZD9833 [ Time Frame: Cycle 1 Day 15 (pre-dose), Cycle 1 Day 15 (2h), Cycle 1 Day 15 (4h) and Cycle 2 Day 1 (pre-dose), (each cycle is 28 days in length) ]The plasma concentrations of AZD9833 at steady state were evaluated.
- Percent Change From Baseline in ER and PgR Expression and Ki67 Labelling Index [ Time Frame: From baseline to Cycle 2 Day 1 (each cycle is 28 days in length) ]The pharmacodynamics of AZD9833 and fulvestrant in a subgroup of patients.
- Changes From Baseline in Health Related Quality of Life (HRQoL) [ Time Frame: From Day 1 until end of treatment and safety follow up (up to data cut-off of 29 months) ]To evaluate the effect of AZD9833 and fulvestrant on the patients' health-related quality of life, as assessed by patient completed HRQoL questionnaires.
- Number of Patients With Adverse Events [ Time Frame: From the date of first dose up to the safety follow-up period (28 days after last dose of AZD9833 and 56 days after last dose of fulvestrant) (up to data cut-off of 29 months) ]The safety and tolerability of AZD9833 when compared to fulvestrant in women with advanced ER-positive HER2-negative breast cancer was evaluated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 130 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Post-menopausal female patients aged at least 18 years.
- Metastatic or loco-regionally recurrent ER-positive HER2-negative adenocarcinoma of the breast.
- Radiological or other objective evidence of progression on or after the last systemic therapy prior to starting study treatment.
- Patients must have at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as ≥10 mm in the longest diameter or in absence of measurable disease as defined above, at least 1 lytic or mixed (lytic+sclerotic) bone lesion.
- Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1.
-
Prior endocrine therapy as follows:
- Recurrence or progression on at least one line of endocrine therapy
- No more than 1 line of endocrine therapy for advanced disease
- No more than 1 line of chemotherapy for advanced disease
- Prior treatment with CDK4/6 inhibitors is permitted
- No prior treatment with fulvestrant, oral selective oestrogen receptor degrader (SERD), or related therapies
- Inclusion criterion for the paired tumour biopsy research subgroup:
Washout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose on-study biopsy.
Exclusion Criteria:
Intervention with any of the following:
- Any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the treatment of breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.
- Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to the first dose of study treatment.
- Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 3A4/5 and sensitive CYP2B6 substrates, and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index or inability to stop use within the washout period prior to receiving the first dose of study treatment.
- Drugs that are known to prolong QT and have a known risk of torsades de pointes.
- The following cardiovascular criteria: QTcF >470 ms, resting heart rate <45 bpm, clinically significant abnormalities of resting electrocardiogram, uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, left ventricular ejection fraction <50%.
- Radiotherapy with a limited field of radiation for palliation within 1 week of dosing, or to > 30% of bone marrow or a wide field within 4 weeks of dosing.
- Major surgical procedure or significant traumatic injury.
- Presence of life-threatening metastatic visceral disease or uncontrolled central nervous system metastatic disease.
- Inadequate bone marrow reserve or organ function.
- Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.
- History of hypersensitivity to active or inactive excipients of AZD9833 or fulvestrant.
- Previous randomisation in the present study.
- Women of childbearing potential.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04214288
Show 91 study locations
Documents provided by AstraZeneca:
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT04214288 |
| Other Study ID Numbers: |
D8530C00002 2019-003706-27 ( EudraCT Number ) |
| First Posted: | January 2, 2020 Key Record Dates |
| Results First Posted: | December 12, 2023 |
| Last Update Posted: | March 7, 2024 |
| Last Verified: | March 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
| Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
| Access Criteria: | When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
| URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Open-Label Parallel-Group Fulvestrant ER-Positive HER2-Negative Breast Cancer |
Metastatic AZD9833 Oral SERD Camizestrant |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Fulvestrant Antineoplastic Agents, Hormonal |
Antineoplastic Agents Estrogen Receptor Antagonists Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |